244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells

Yi Zhang, Ke Yao, Chengcheng Shi, Yanan Jiang, Kangdong Liu, Song Zhao, Hanyong Chen, Kanamata Reddy, Chengjuan Zhang, Xiaoyu Chang, Joohyun Ryu, Ann M. Bode, Ziming Dong, Zigang Dong

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer(NSCLC). Several EGFR tyrosine kinase inhibitors(TKIs), such as gefitinib, have been used as effective clinical therapies for patients with NSCLC. Unfortunately, acquired resistance to gefitinib commonly occurs after 6-12 months of treatment. The resistance is associated with the appearance of the L858R/T790M double mutation of the EGFR. In our present study, we discovered a compound,referred to as 244-MPT, which could suppress either gefitinib-sensitive or -resistant lung cancer cell growth and colony formation, and also suppressed the kinase activity of both wildtype and double mutant (L858R/T790M) EGFR. The underlying mechanism reveals that 244-MPT could interact with either the wildtype or double-mutant EGFR in an ATP-competitive manner and inhibit activity. Treatment with 244-MPT could substantially reduce the phosphorylation of EGFR and its downstream signaling pathways, including Akt and ERK1/2 in gefitinib-sensitive and -resistant cell lines. It was equally effective in suppressing EGFR phosphorylation and downstream signaling in NL20 cells transfected with wildtype, single-mutant (L858R) or mutant (L858R/T790M) EGFR. 244-MPT could also induce apoptosis in a gefitinib-resistant cell line and strongly suppress gefitinib-resistant NSCLC tumor growth in a xenograft mouse model. In addition, 244-MPT could effectively reduce the size of tumors in a gefitinib-resistant NSCLC patient-derived xenograft (PDX) SCID mouse model. Overall, 244-MPT could overcome gefitinib-resistance by directly targeting the EGFR.

Original languageEnglish (US)
Pages (from-to)44274-44288
Number of pages15
JournalOncotarget
Volume6
Issue number42
DOIs
StatePublished - 2015

Bibliographical note

Funding Information:
The authors thank Todd Schuster and Alyssa Langfald for supporting experiments, Katrina Plueger for animal experiments and Nicki Brickman for assistance in submitting our manuscript (The Hormel Institute, University of Minnesota). This work was supported by National Institutes of Health grants: CA166011 (Z. Dong), CA172457 (Z. Dong), R37 CA81064 (Z. Dong), and CA187027 (Z. Dong), The Hormel Foundation, and National Natural Science Foundation of China, NSFC Number: 81000926 (Z. Dong).

Keywords

  • Epidermal growth factor receptor (EGFR)
  • Gefitinib resistance
  • Non-small cell lung cancer (NSCLC)

Fingerprint

Dive into the research topics of '244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells'. Together they form a unique fingerprint.

Cite this